The subgroup analysis showed that a higher CPN2 predicted a worse survival outcome in the adenocarcinoma group (P < 0.001, Figure 2B), but not in the squamous cell carcinoma group (P > 0.05, Figure 2C). Here, CPN2 is linked to adenocarcinoma.